Hallmarks of neurodegeneration

Precious samples. Hard-to-detect biomarkers. Abcam’s sensitive recombinant antibodies and sensitive assays are optimized to detect low-abundance proteins to help you get it right first time, every time, and consistently over time, so you can de-risk your research and get more from limited samples.Neurodegeneration refers to the gradual structural and functional deterioration of neurons in the central or peripheral nervous system, arising from a convergence of molecular disturbances that eventually exceed the neuron's capacity to compensate. Because mature neurons cannot be readily replaced, this loss disrupts circuits that govern memory, movement, cognition, and sensory processing, leading to clinical syndromes recognized as neurodegenerative diseases (NDDs).

To make sense of the biological overlap between disorders as different as Alzheimer disease (AD), Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington disease (HD), and prion disease (PrD), researchers have proposed a shared conceptual scaffold: a set of hallmarks that recur across NDDs, with disease-specific weighting¹.

This approach mirrors the influential hallmarks frameworks developed for aging² and cancer³. The current consensus identifies eight hallmarks: pathological protein aggregation, synaptic and neuronal network dysfunction, aberrant proteostasis, cytoskeletal abnormalities, altered energy homeostasis, DNA and RNA defects, inflammation, and neuronal cell death¹.

An integrated view of the eight hallmarks

What qualifies as a hallmark?

1. Pathological protein aggregation

The accumulation of misfolded proteins into insoluble deposits is the most iconic feature of NDDs, so much so that many disorders are described as "proteinopathies." Different diseases are defined by distinct aggregating species: amyloid-β and tau in AD, α-synuclein in PD and Lewy body disease, TDP-43 and FUS in ALS/FTD, huntingtin in HD, and prion protein in PrD⁴. Familial mutations in the corresponding genes typically increase the propensity of the encoded protein to misfold, pointing to a toxic gain-of-function mechanism⁵.

A key insight from prion biology is that misfolded species can act as self-templating seeds, recruiting native protein and propagating between cells. Similar "prion-like" behavior has been documented for α-synuclein, tau, TDP-43, and huntingtin.

Unlike classical prions, there is no evidence of transmission between individuals in these contexts¹. The field increasingly moves beyond viewing mature fibrils as the primary toxic species. Soluble oligomeric intermediates, distributed across the cytoplasmic, nuclear, and synaptic compartments, are widely regarded as more directly neurotoxic⁶.

2. Synaptic and neuronal network dysfunction

Long before neurons are lost, their communication fails. Synaptic dysfunction is now recognized as an early and, in many cases initiating event in AD, PD, HD, ALS, and FTD¹. Because synaptic transmission depends on precisely coordinated neurotransmitter release, calcium buffering, cytoskeletal remodeling, and local ATP production, it is exquisitely sensitive to upstream disturbances in mitochondrial function, proteostasis, and axonal transport.

One of the best-characterized mechanisms is glutamate-driven excitotoxicity. Excessive glutamate signaling drives uncontrolled Ca²⁺ entry, which in turn compromises mitochondrial function, activates calcium-dependent proteases such as calpains, and triggers degradation of structural and functional macromolecules¹. Synaptic loss is also shaped by non-cell-autonomous processes, notably inappropriate synapse elimination by microglia through complement-mediated pruning⁷.

3. Aberrant proteostasis

Neurons rely on two integrated systems to preserve proteome integrity: the ubiquitin-proteasome system (UPS), which selectively degrades tagged proteins, and the autophagy-lysosome pathway (ALP), which clears aggregates, damaged organelles, and dysfunctional mitochondria through mitophagy⁸. Both systems are linked by the adaptor p62 (SQSTM1), which delivers ubiquitinated cargo to the autophagosome.

Genetic evidence firmly implicates proteostasis in neurodegeneration. Mutations in UBQLN2 and VCP disrupt UPS function and cause ALS/FTD, while Parkin mutations impair ubiquitin ligase activity in PD¹. Conversely, aggregation-prone proteins such as tau, α-synuclein, and TDP-43 inhibit proteasomal throughput, establishing a vicious cycle. The neurological phenotypes of lysosomal storage disorders, including Niemann-Pick type C and Gaucher disease, the latter linked to PD through GBA, further underscore how lysosomal dysfunction can drive neurodegeneration⁹.

4. Cytoskeletal abnormalities

The extreme morphology of neurons places unusual demands on their cytoskeleton, composed of microtubules, neurofilaments, and actin filaments. This scaffolding maintains cellular architecture, supports synaptic plasticity, and drives long-range axonal transport of organelles, mRNAs, and signaling complexes¹.

When cytoskeletal integrity or axonal transport fails, neurons often degenerate in a distal-to-proximal, or "dying-back," pattern, a hallmark of ALS, spinal-bulbar muscular atrophy, and many peripheral neuropathies¹⁰. Beyond its mechanistic role, cytoskeletal breakdown has yielded one of the most impactful biomarkers in modern neurology: neurofilament light chain (NfL), released from damaged axons, reaches the CSF and blood, where it can be quantified as a sensitive, disease-agnostic indicator of ongoing neuroaxonal injury¹¹.

5. Altered energy homeostasis

Neurons are metabolically expensive cells, and their reliance on mitochondrial ATP production makes them acutely vulnerable to bioenergetic failure¹². Most of this energy is required to sustain ion gradients, synaptic vesicle cycling, and calcium buffering. Impaired oxidative phosphorylation not only reduces ATP supply but also generates reactive oxygen species (ROS) that oxidize lipids, proteins, and nucleic acids.

Inherited mutations provide direct evidence linking faulty mitochondrial quality control to NDDs: PINK1 and Parkin cooperate in mitophagy and are mutated in early-onset PD, and mitofusin-2 mutations cause Charcot-Marie-Tooth disease¹³. Beyond such rare cases, mitochondrial dysfunction broadly contributes to AD, HD, and ALS. The resulting energy deficit reverberates outward: calcium mishandling, protease activation, and impaired organelle turnover all trace back, in part, to compromised mitochondria¹.

6. DNA and RNA defects

Because neurons are post-mitotic, they cannot dilute genomic damage through cell division and must instead rely on continuous repair. The pronounced neurological phenotypes of recessive DNA repair syndromes, particularly those affecting single-strand break resolution, illustrate this dependence and demonstrate that unresolved damage triggers transcriptional stalling and death in non-dividing cells¹.

RNA metabolism has emerged as an equally critical axis, especially in ALS and FTD. TDP-43 and FUS are nuclear RNA-binding proteins that, when mislocalized to the cytoplasm, disrupt splicing, transport, and stability of hundreds of transcripts¹⁴. These same proteins participate in stress granules, dynamic ribonucleoprotein assemblies that, when persistent, seed pathological aggregation¹⁵. Together, DNA and RNA defects link genomic maintenance, transcription, and proteinopathy into a single continuum.

7. Inflammation

Chronic neuroinflammation, sustained by microglia and astrocytes, is a near-universal feature of NDDs¹⁶. Microglia normally survey the CNS for damage and pathogens, but persistent activation, driven by protein aggregates, damaged synapses, or oxidative stress, shifts them into disease-associated states that release cytokines, ROS, and complement, thereby exacerbating neuronal injury¹.

Human genetic studies have highlighted microglia as central players in Alzheimer’s disease. Complete loss of TREM2 function causes Nasu-Hakola disease, while partial loss-of-function TREM2 variants increase susceptibility to Alzheimer’s disease. TREM2 acts together with ApoE to shift microglia from a homeostatic, surveillance state into a disease-associated phenotype¹⁷. Astrocytes contribute in parallel: reactive astrocytes lose their capacity for efficient glutamate uptake and begin secreting neurotoxic factors, while ongoing signaling between astrocytes and microglia reinforces the local inflammatory environment¹⁸.

8. Neuronal cell death

Neuronal loss is the endpoint to which all other hallmarks converge. The intrinsic vulnerability of neurons reflects their post-mitotic state, high energy demand, extreme morphology, and dependence on glial support¹. Multiple death programs contribute, apoptosis and necrosis remain the best characterized, but necroptosis, ferroptosis, pyroptosis, phagoptosis, and autophagy-dependent death are all implicated¹⁹.

The immediate triggers of neuronal death read like a summary of the preceding hallmarks: excitotoxic calcium influx, protein aggregation, lysosomal rupture, unresolved DNA damage, oxidative stress, and loss of trophic input¹. This interconnection is precisely why neurodegeneration is best understood as a multi-hit process rather than the failure of a single pathway.

How are the hallmarks interconnected?

The eight hallmarks are not parallel phenomena but nodes in a tightly coupled network. Synaptic dysfunction and excitotoxicity feed directly into bioenergetic collapse and oxidative stress; failing proteostasis amplifies protein aggregation, which in turn impairs synaptic function and mitochondrial dynamics; DNA damage arises from ROS produced by dysfunctional mitochondria; and glial responses modulate and are modulated by each of these processes¹. The practical consequence is that neuronal resilience does not fail with a single insult but is overwhelmed when several hallmarks act simultaneously and reinforce one another.

How do hallmark contributions differ across NDDs?

Although the eight hallmarks recur across NDDs, their relative contributions vary considerably among disorders, providing a mechanistic basis for molecular classification.

In AD, the dominant axes are amyloid-β and tau aggregation, impaired proteostasis, synaptic dysfunction, and neuroinflammation. PD is characterized primarily by proteostasis failure and mitochondrial dysfunction, as reflected in strong genetic association with PINK1, Parkin, LRRK2, and GBA. ALS integrates protein aggregation with disrupted RNA and DNA metabolism and synaptic/network dysfunction, while cytoskeletal and axonal transport defects predominate in peripheral neuropathies and motor axonopathies.

Inflammation is the principal driver of multiple sclerosis, and templated propagation of misfolded protein defines prion diseases¹. Applied systematically, this framework enables both cross-disease stratification and molecular subtyping within individual NDDs, a prerequisite for mechanism-driven diagnostic criteria.

How does the hallmark framework shape NDD basic and translational research?

The interconnected architecture of the hallmarks has direct consequences for how NDD research is designed and interpreted. In basic research, the framework encourages investigators to situate individual molecular findings within the broader hallmark network rather than treating pathways such as proteostasis, mitochondrial function, or RNA metabolism in isolation. Mechanistic studies increasingly examine how perturbating one hallmark propagates to others, providing a more integrated view of pathogenesis¹.

In translational research, compensatory crosstalk among hallmarks means that single-target interventions may be blunted by adjacent pathways, providing a mechanistic rationale for combinatorial, multi-pathway strategies¹.

Preclinical models are expected to recapitulate several hallmarks rather than a single pathological feature, and molecular subtyping based on dominant hallmark profiles is emerging as a key variable in cohort selection and endpoint definition, addressing a major source of variability in NDD target validation and mechanism-of-action studies²⁰.

FAQs

Related resources

For deeper mechanistic and target-focused coverage of individual hallmarks and diseases discussed above, see the related Abcam educational pages:

• Neuroinflammation
• Amyloid-β
• Tau
• Alzheimer disease
• Parkinson disease
• Huntington disease
• Amyotrophic lateral sclerosis (ALS)

References

1. Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693–714.
2. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243–278.
3. Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12(1):31–46.
4. Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21(10):1332–1340.
5. Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annu Rev Biochem. 2017;86:27–68.
6. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15(3):349–357.
7. Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712–716.
8. Menzies FM, Fleming A, Caricasole A, et al. Autophagy and neurodegeneration: Pathogenic mechanisms and therapeutic opportunities. Neuron. 2017;93(5):1015–1034.
9. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983–997.
10. Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci. 2014;15(6):394–409.
11. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–589.
12. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–795.
13. Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015;85(2):257–273.
14. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416–438.
15. Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat Rev Neurosci. 2019;20(11):649–666.
16. Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359–1369.
17. Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I. Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell. 2018;173(5):1073–1081.
18. Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–487.
19. Fricker M, Tolkovsky AM, Borutaite V, Coleman M, Brown GC. Neuronal cell death. Physiol Rev. 2018;98(2):813–880.
20. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954–963.
21. Karikari TK, Ashton NJ, Brinkmalm G, et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18(7):400–418.